Cell Therapy News Volume 26.22 | Dec 01 2025

    0
    31







    2025-12-01 | CTN 26.22


    Cell Therapy News by STEMCELL Technologies
    Vol. 26.22 – 1 December, 2025

    TOP STORY

    IL-9 Signaling Redirects CAR T Cell Fate toward CD8+ Memory and CD4+ Cycling States, Enhancing Antitumor Efficacy

    Investigators demonstrated that endowing CAR T cells with ectopic interleukin (IL)-9 signaling by co-expressing an IL-9 receptor rewires CAR T cell fate under antigen stress to enhance antitumor efficacy.
    [Immunity]

    AbstractGraphical Abstract
    PUBLICATIONSListed by the impact factor of the journal

    In Situ Chimeric Antigen Receptor Macrophage Therapy via Co-Delivery of mRNA and Immunostimulant

    Researchers reported an in situ CAR-macrophage therapy. By leveraging lipid nanoparticles designed to selectively transfect tumor-associated macrophages, they circumvent extensive ex vivo manipulation and achieve robust CAR expression directly within the tumor microenvironment.
    [ACS Nano]

    AbstractGraphical Abstract

    A Yeast Surface Display Platform for Characterizing CAR T Cell Responses to Cancer Antigens

    The authors presented an engineered yeast-based antigen system for the simulation of cancer cells with precise regulation of surface-antigen densities, providing a tool for controlled activation of CAR T cells and systematic assessment of antigen density effects.
    [Nature Communications]

    Full Article

    Multiplex Gene-Editing Strategy to Engineer Allogeneic EGFR-Targeting CAR T Cells with Improved Efficacy against Solid Tumors

    Scientists described a multifaceted approach to engineer allogeneic CAR T cells resistant to both biochemical and immunological inhibitory signaling using an adenine base editor and a CRISPR-Cas12b nuclease.
    [Nature Communications]

    Abstract

    Anti-BCMA/CD19 CAR T Cell Therapy in Patients with Refractory Generalized Myasthenia Gravis: A Single-Arm, Phase I Trial

    Researchers developed autologous anti-B-cell maturation antigen (BCMA) and CD19 bispecific CAR T cells to evaluate the safety and efficacy in refractory myasthenia gravis.
    [EClinicalMedicine]

    Full Article

    Anti-uPAR CAR T Cells Reverse and Prevent Aging-Associated Defects in Intestinal Regeneration and Fitness

    Scientists identified the accumulation of epithelial urokinase plasminogen activator receptor (uPAR)-positive cells in the aging gut and uncovered their impact on intestinal stem cells function in aging.
    [Nature Aging]

    Full Article

    Base Edited “Universal” Donor CAR T Cell Strategies for Acute Myeloid Leukemia

    Investigators reported that monotherapy using base-edited “universal” donor CAR T cells against CD33, CLL-1, or CD7 delivered inhibition of acute myeloid leukemia in immunodeficient mice when antigen expression was homogenous.
    [Leukemia]

    Full Article

    Targeting Orthotopic and Metastatic Pancreatic Cancer with Allogeneic Stem Cell-Engineered Mesothelin-Redirected CAR-NKT Cells

    Researchers developed an off-the-shelf immunotherapy using gene-engineered natural killer T cells derived from stem cells called Allo15MCAR-NKT cells.
    [Proceedings of The National Academy of Sciences of The United States of America]

    Full Article

    Bone Marrow Blasts- and Modified EASIX-Guided Risk Stratification for Coagulopathy and Outcomes after CAR-T Therapy in Relapsed/Refractory B-ALL

    An effective CAR-T-associated coagulopathy (CARAC) risk prediction and stratification model was established. High-risk CARAC patients, particularly CARAC-disseminated intravascular coagulation, were associated with significantly worse outcomes.
    [Thrombosis Research]

    Full Article

    Evaluation of Dasatinib and Ponatinib for the Control of CD123 CAR T Cell Functionalities

    Investigators evaluated the capacity of two tyrosine kinase inhibitors, dasatinib and ponatinib, to reversibly inhibit CAR T cell functions.
    [Molecular Therapy Oncology]

    AbstractGraphical Abstract
    2025 Rare Disease SciComm Award - Submit Your Application
    REVIEWS

    CAR-T Cell Exhaustion in B Cell Lymphoma: Current Status, Mechanisms, and Potential Solutions

    The authors discuss the current situation of CAR-T therapies in the clinical treatment of lymphoma patients, the mechanisms of CAR-T cell exhaustion, and potential strategies to overcome CAR-T cell exhaustion, thereby bringing hope to improve therapeutic outcomes for lymphoma patients.
    [Molecular Therapy Oncology]

    AbstractGraphical Abstract
    INDUSTRY AND POLICY NEWS

    Shield against Metastases and Genetically Protected CAR-T Cells: Double Honor for Mirco Julian Friedrich

    Physician and cancer researcher Mirco Julian Friedrich from the German Cancer Research Center (DKFZ), the stem cell research institute HI-STEM*, and Heidelberg University Hospital has received two awards for two independent research projects.
    [DKFZ]

    Press Release

    Novartis Receives FDA Approval for Itvisma®, the Only Gene Replacement Therapy for Children Two Years and Older, Teens, and Adults with Spinal Muscular Atrophy (SMA)

    Novartis announced that the US FDA has approved Itvisma® for the treatment of children two years and older, teens, and adults living with SMA with a confirmed mutation in the survival motor neuron 1 gene, making it the first and only gene replacement therapy available for this broad population.
    [Novartis]

    Press Release
    FEATURED EVENT

    WORD+ Research Day

    February 4-5, 2026
    Cambridge, England, United Kingdom

    > See All Events

    JOB OPPORTUNITIES

    Specialist – Stem Cell Transplant and Cellular Therapy

    The University of Iowa – Iowa City, Iowa, United States

    Assistant Professor – Physiology

    Midwestern University – Glendale, Arizona, United States

    Researcher – Pharmacy and Pharmaceutical Sciences

    St Jude Children’s Research Hospital – Memphis, Tennessee, United States

    Faculty Position – Cancer Immunotherapy

    Fred Hutchinson Cancer Center – Seattle, Washington, United States

    Postdoctoral Associate – Translational Immunotherapy

    Baylor College of Medicine – Houston, Texas, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2